| Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer C Fumarola, MA Bonelli, PG Petronini, RR Alfieri Biochemical pharmacology 90 (3), 197-207, 2014 | 488 | 2014 |
| Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and … G Mazzaschi, D Madeddu, A Falco, G Bocchialini, M Goldoni, F Sogni, ... Clinical cancer research 24 (2), 407-419, 2018 | 234 | 2018 |
| Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells1 M Brigotti, R Alfieri, P Sestili, M Bonelli, PG Petronini, A Guidarelli, ... The FASEB Journal 16 (3), 365-372, 2002 | 196 | 2002 |
| The translational machinery of human CD4+ T cells is poised for activation and controls the switch from quiescence to metabolic remodeling S Ricciardi, N Manfrini, R Alfieri, P Calamita, MC Crosti, S Gallo, R Müller, ... Cell metabolism 28 (6), 895-906. e5, 2018 | 162 | 2018 |
| Hyperosmotic stress response: comparison with other cellular stresses RR Alfieri, PG Petronini Pflügers Archiv-European Journal of Physiology 454, 173-185, 2007 | 146 | 2007 |
| 5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity C Carmi, A Cavazzoni, V Zuliani, A Lodola, F Bordi, PV Plazzi, RR Alfieri, ... Bioorganic & medicinal chemistry letters 16 (15), 4021-4025, 2006 | 132 | 2006 |
| Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis RR Alfieri, A Cavazzoni, PG Petronini, MA Bonelli, AE Caccamo, ... The Journal of Physiology 540 (2), 499-508, 2002 | 125 | 2002 |
| Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones A Cavazzoni, MA Bonelli, C Fumarola, S La Monica, K Airoud, R Bertoni, ... Cancer letters 323 (1), 77-87, 2012 | 114 | 2012 |
| Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer C Carmi, M Mor, PG Petronini, RR Alfieri Biochemical pharmacology 84 (11), 1388-1399, 2012 | 112 | 2012 |
| Combined inhibition of CDK4/6 and PI3K/AKT/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells MA Bonelli, G Digiacomo, C Fumarola, R Alfieri, F Quaini, A Falco, ... Neoplasia 19 (8), 637-648, 2017 | 109 | 2017 |
| Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility A Ravelli, G Roviello, D Cretella, A Cavazzoni, A Biondi, MR Cappelletti, ... Tumor Biology 39 (4), 1010428317695023, 2017 | 106 | 2017 |
| Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines S La Monica, M Galetti, RR Alfieri, A Cavazzoni, A Ardizzoni, M Tiseo, ... Biochemical pharmacology 78 (5), 460-468, 2009 | 104 | 2009 |
| Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents SA Al-Trawneh, JA Zahra, MR Kamal, MM El-Abadelah, F Zani, M Incerti, ... Bioorganic & medicinal chemistry 18 (16), 5873-5884, 2010 | 99 | 2010 |
| Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress RR Alfieri, MA Bonelli, A Cavazzoni, M Brigotti, C Fumarola, P Sestili, ... The Journal of physiology 576 (2), 391-401, 2006 | 95 | 2006 |
| Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis C Fumarola, S La Monica, RR Alfieri, E Borra, GG Guidotti Cell Death & Differentiation 12 (10), 1344-1357, 2005 | 95 | 2005 |
| Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines S La Monica, D Cretella, M Bonelli, C Fumarola, A Cavazzoni, ... Journal of Experimental & Clinical Cancer Research 36, 1-12, 2017 | 92 | 2017 |
| The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells D Cretella, A Ravelli, C Fumarola, S La Monica, G Digiacomo, ... Journal of Experimental & Clinical Cancer Research 37, 1-12, 2018 | 91 | 2018 |
| Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation M Bonelli, S La Monica, C Fumarola, R Alfieri Biochemical pharmacology 170, 113676, 2019 | 87 | 2019 |
| Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines A Cavazzoni, RR Alfieri, C Carmi, V Zuliani, M Galetti, C Fumarola, ... Molecular cancer therapeutics 7 (2), 361-370, 2008 | 87 | 2008 |
| Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides C Carmi, E Galvani, F Vacondio, S Rivara, A Lodola, S Russo, S Aiello, ... Journal of medicinal chemistry 55 (5), 2251-2264, 2012 | 83 | 2012 |
